卡迪根 KARD

David Meeker, M.D. has served on our board of directors since October 2024. Dr. Meeker has served as Chair, President and Chief Executive Officer of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company (Nasdaq: RYTM), since July 2020. Dr. Meeker has also served as a director of Rhythm Pharmaceuticals, Inc. since November 2015 and as its chairman of the board since April 2017. Previously, Dr. Meeker served as Chief Executive Officer of KSQ Therapeutics, Inc., a biotechnology company, from October 2017 to July 2020. From October 2011 until June 2017, Dr. Meeker served as President and CEO of Genzyme Corporation and subsequently as EVP, Head of Sanofi Genzyme, a unit of Sanofi S.A., a global pharmaceutical company. Dr. Meeker oversaw the company's specialty business units-Rare Diseases, Multiple Sclerosis, Oncology and Immunology. He has also served as chairman of the board of directors of Trevi Pharmaceuticals, Inc. (Nasdaq: TRVI) since July 2017 and as chair of the board of directors of Pharvaris N.V. (Nasdaq: PHVS) since January 2021. Dr. Meeker completed his internal medicine residency at Harvard's Beth Israel Hospital and pulmonary/critical care training at Boston University. He holds an M.D. degree from the University of Vermont Medical School, did his medical training in Internal Medicine, and pulmonary/critical care, and completed the Advanced Management Program at Harvard Business School in 2000.

Kim Popovits has served on our board of directors since September 2024. Ms. Popovits served as President and Chief Executive Officer of Genomic Health, Inc., a healthcare company, from January 2009 until its acquisition by Exact Sciences in November 2019. Prior to that role, Ms. Popovits served as Genomic Health's Chief Operating Officer from 2002 to 2009 and as its chairman of the board of directors from 2012 to 2019. Ms. Popovits has served as a director of Exact Sciences Corp (Nasdaq: EXAS) since January 2025, Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) since May 2018, 10x Genomics, Inc. (Nasdaq: TXG) since March 2020, and Talis Biomedical Corporation (formerly Nasdaq: TLIS) since March 2020. Ms. Popovits holds a B.A. in business from Michigan State University.

Paul Berns has served on our board of directors since June 2024. Mr. Berns is a Managing Director with ARCH Venture Partners. Mr. Berns has been a member of ARCH Venture Partners since August 2018 and became a Managing Director in 2021. Mr. Berns is the Co-founder and Executive Chairman of both Tenvie Therapeutics, Inc. and Ollin Biosciences, Inc. Mr. Berns was also the Co-founder and Chairman of the Board of Directors for HI-Bio prior to its acquisition by Biogen, Inc. in July 2024, as well as a Co-founder and Lead Independent Director of Metsera Inc. prior to its acquisition by Pfizer in November 2025. Mr. Berns is the Co-founder, Chief Executive Officer and Chairman of Neumora Therapeutics, Inc. (Nasdaq: NMRA), Co-founder and member of the Board of Directors of Salma Health, and currently serves as Chairman of the Board of Directors of the privately held company Happy AI, and is a member of the Board of Directors of Mirador Therapeutics, Rhygaze, and Epirium. Mr. Berns has served as a director of Unity Biotechnology, Inc. (Nasdaq: UBX) from March 2018 to April 2025, EQRx, Inc., from January 2020 up to its acquisition by Revolution Medicines, Inc. in November 2023, and Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a publicly-traded pharmaceutical company, from April 2010 to July 2021. Mr. Berns holds a B.S. in Economics from the University of Wisconsin.

On September 29, 2026, the Board appointed Kristin Reinke to serve as a Class I director, to hold office until the Company's annual meeting of stockholders in 2027 or until her earlier death, resignation or removal, effective as of September 29, 2026. Ms. Reinke is currently vice president of finance at Google, where she leads the application of AI to modernize and scale the company's finance organization. A member of Google's finance leadership team since 2005, she has held roles spanning global FP&A, capital allocation, and controllership, helping the company grow from a startup into a multibillion-dollar global enterprise. She previously held leadership roles at Oracle and began her career at Arthur Andersen. Ms. Reinke serves on the board of Everly Health as an independent director and the audit committee chair. She is a CPA and holds a bachelor's degree in accounting from Michigan State University.

Andy Pasternak has served as our Chief Strategy Officer since January 2026. Prior to joining Kardigan, Mr. Pasternak served as an Advisory Partner at Bain & Company, a global management consulting firm, from March 2024 to December 2025. Prior to that, Mr. Pasternak served as Executive Vice President and Chief Strategy Officer at Horizon Therapeutics plc from November 2019 until its acquisition by Amgen Inc. in October 2023. Mr. Pasternak has served as Chairman of the board of directors at Context Therapeutics (Nasdaq: CNTX) since January 2025 and served on the board of directors of Endo, Inc. from April 2024 to August 2025. He is also an adjunct lecturer and advisory board member in the Healthcare at the Kellogg School of Management at Northwestern University. Mr. Pasternak holds a B.A. in economics from Northwestern and an MBA from the University of Chicago.

Brianne Puglisi has served as our Chief Financial Officer since November 2024. Prior to joining us, Ms. Puglisi served as Chief Business Officer for LianBio (formerly Nasdaq: LIAN) from February 2020 to January 2025. Previously, from April 2012 to January 2020, she was Senior Vice President of Finance and Strategic Operations at Kadmon Pharmaceuticals (formerly Nasdaq: KDMN) prior to its acquisition by Sanofi S.A. She has also held a senior-level position at KPMG LLP. Ms. Puglisi holds a B.B.A. degree from the University of Massachusetts, Amherst, and an MBA from New York University.

Tim Walbert has served on our board of directors since May 2026. Mr. Walbert is currently a senior advisor to Patient Square Capital since April 2026 and senior advisor to Amgen, Inc. (Nasdaq: AMGN), a biotechnology company, a position he has held since October 2023. Mr. Walbert was previously Chairman, President and Chief Executive Officer of Horizon Therapeutics plc from June 2008 to October 2023. Before joining Horizon Therapeutics plc, he was President, Chief Executive Officer and Director of IDM Pharma Inc., a biotechnology company. Before IDM Pharma Inc., Mr. Walbert served as Executive Vice President, Commercial Operations at NeoPharm Inc., a biotechnology company. From 2001 to 2005, he was Divisional Vice President and General Manager, Immunology, at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA, and served as Divisional Vice President, Global Cardiovascular Strategy. From 1998 to 2001, Mr. Walbert served as Director, CELEBREX North America, and Arthritis team Leader, Asia Pacific, Latin America and Canada, at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co. Inc. and Wyeth. Mr. Walbert currently serves on the boards of Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), Sagimet Biosciences, Inc. (Nasdaq: SGMT), and Century Therapeutics, Inc. (Nasdaq: IPSC). He previously served on the board of directors for Aurinia Pharmaceuticals, Inc. (Nasdaq: AUPH) from 2020 to 2022, Exicure Inc. (Nasdaq: XCUR) from 2019 to 2022, Assertio Holdings Inc. (Nasdaq: ASRT) from 2014 to 2020, Raptor Pharmaceutical Corp. from 2010 to 2014; XOMA Corporation from 2011 to 2017, and Sucampo Pharmaceuticals Inc. from 2016 to 2018. Mr. Walbert received a Bachelor of Arts in business from Muhlenberg College in Allentown, PA.

Jay Edelberg, M.D., Ph.D. has served as our Co-Founder and Chief Medical Officer since August 2023. Dr. Edelberg co-founded Prolaio, Inc. in December 2021 and served as its Head of Research and Development and a member of its board of directors prior to our acquisition of Prolaio, Inc. in February 2025. Prior to this, Dr. Edelberg was Chief Medical Officer for MyoKardia, Inc. from February 2019 to November 2020, when it was acquired by Bristol Myers Squibb (NYSE: BMY), and served as Senior Vice President of Global Drug Development at Bristol Myers Squibb from November 2020 to October 2021. Dr. Edelberg trained at the Massachusetts General Hospital (Internal Medicine), the Beth Israel Deaconess Medical Center in Boston (Cardiovascular Medicine) and Massachusetts Institute of Technology (Biology). He holds a B.S. in bioengineering from Columbia University, and an M.D. and Ph.D. from Duke University.

John B. Moriarty, Jr., J.D. has served as our Chief Legal Officer since April 2026. Previously, Mr. Moriarty served as Chief Legal Officer at Avidity Biosciences, Inc. from August 2024 through and following the completion of its acquisition by Novartis in March 2026. Prior to this, Mr. Moriarty served as Executive Vice President, Chief Legal Officer and Corporate Secretary at Mirati Therapeutics from May 2023 through the completion of its acquisition by BMS Co. in January 2024. From September 2020 to April 2023, Mr. Moriarty served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Olema Pharmaceuticals, Inc. Mr. Moriarty received a B.A. from the University of Virginia and a J.D. cum laude from the University of Georgia School of Law.